SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as investors debate its potential for a major breakout, with sentiment heavily influenced by speculation around upcoming institutional developments and broader market momentum. While some traders express frustration over price volatility, the community remains divided between those expecting parabolic gains from the current consolidation phase and skeptics wary of its long-term utility.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

RETIRE is trending as community members position the project as a tokenized alternative to traditional retirement plans, actively discussing it as a movement against established financial systems. Supporters are highlighting the project's locked liquidity and active community efforts as catalysts for potential long-term growth and financial independence.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as retail investors react to the ongoing volatility and rapid price action within the biotech sector, heavily driven by recent buyout speculation and M&A activity. Community discussion is focused on the potential for further sector rotation, with many traders debating the sustainability of the current rally against a backdrop of macroeconomic uncertainty.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X Shares

Investors are actively debating the viability of holding the Direxion Daily S&P Biotech Bear 3X Shares as biotechnology stocks maintain persistent upward momentum and defy bearish expectations. Community sentiment is deeply divided, with some participants expressing intense frustration over consistent losses and the asset's decay, while others continue to hunt for entry points, awaiting a potential sector correction or a breakout above key technical resistance levels in the broader biotech index.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading activity and community speculation driven by its IoT and data ecosystem narrative, with investors closely watching technical indicators and ecosystem developments for a potential move. While some traders are aggressively accumulating, others remain cautious, highlighting the high volatility and ongoing debate regarding the project's long-term utility.

LendingClub Corp. engages in the operations of digital marketplace banks. It operates through the LendingClub Bank and LendingClub Corporation (Parent Only) segments. The LendingClub Bank segment is involved in the provision of full complement of financial products and solutions, loans, leases, and deposits. The LendingClub Corporation (Parent Only) segment includes the holding company legal entity. The company was founded by Renaud Laplanche and Soulaiman Htite on October 2, 2006 and is headquartered in San Francisco, CA.

LendingClub Corp

LendingClub is generating buzz as investors weigh the stock's strong fundamentals and value-oriented growth against peers like SoFi, with the market closely monitoring the company's rebranding efforts and potential interest rate shifts. Community discourse highlights a divide between those bullish on its defensive, bank-model stability and those frustrated by its conservative marketing compared to more aggressive fintech competitors.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

Mullen is trending as the community rallies around a series of crypto tokens, with discussions heavily focused on speculative price movements and comparisons to past volatility. Participants are actively coordinating pump efforts while trading accusations of scams and rug pulls, reflecting the high-risk, community-driven nature of the current activity surrounding these assets.

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Argen X SE - ADR

Argenx

Argenx is seeing active community discussion following the recent FDA approval expanding the use of VYVGART and VYVGART Hytrulo to all adult patients with generalized myasthenia gravis. Investors are debating the stock's future momentum and commercial scaling potential while weighing the impact of emerging market competition in the broader immunology sector.

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Danaher Corp.

Danaher Corp is trending as investors react to a significant acquisition announcement involving Masimo, which has sparked mixed sentiment regarding integration risks versus long-term diagnostics expansion. Market participants are also weighing the company's recent earnings performance and core business guidance against broader volatility in the medical device and biotechnology sectors.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending due to anticipation surrounding the upcoming ESMO presentation of late-breaking CHOPIN trial data, which investors hope will validate Hepzato's efficacy in combination with immunotherapy and drive broader adoption. The community is actively discussing the stock's valuation relative to its commercial progress and the potential for clinical trial success to catalyze a significant rerating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View

Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.

SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback

Summit Therapeutics posts narrower Q1 loss but stock plunges 25% after ivonescimab setback, raising concerns over its late-stage cancer pipeline progress.

HC Wainwright Issues Pessimistic Forecast for Summit Therapeutics (NASDAQ:SMMT) Stock Price

HC Wainwright reduced their price target on Summit Therapeutics from $30.00 to $23.00 and set a "buy" rating for the company in a report on Monday...

Summit Therapeutics (NASDAQ:SMMT) Issues Earnings Results

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by...

Summit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street Zen

Wall Street Zen upgraded shares of Summit Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday...

<ul class="summary-bullets"><li>Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier.</li><li>Piper Sandler lowered its price target on Summit to $16 from $17 and maintained a ‘Neutral’ rating on the shares.</li><li>The company’s interim update from its HARMONi-3 trial disappointed investors.&nbsp; Final data from the cohort remain on track for the second half of 2026.</li></ul> Shares of Summit Therapeutics Inc. (SMMT) closed 25% lower on Friday after the company reported a wider loss for the first quarter and an interim analysis update from its HARMONi-3 trial, prompting Piper Sandler to lower its price target on the stock.Piper Sandler lowered its price target on Summit to $16 from $17 and maintained a ‘Neutral’ rating on the shares.<h2 class="st-heading-2">Summit’s Q1 Earnings</h2>Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier, as the company ramps up spending on its lead asset ivonescimab in the treatment of non-small cell lung cancer (NSCLC).The company is studying Ivonescimab combined with chemotherapy in patients with first-line metastatic NSCLC in its HARMONi-3 trial, with two distinct cohorts to be analyzed separately for squamous tumors and non-squamous tumors.In squamous tumors, an independent Data Monitoring Committee completed a pre-specified interim progression-free survival analysis in Q2 2026 and recommended that the study continue as planned with no safety concerns, the company said. However, it did not hit the high statistical bar for early success/stop. Final data from the cohort remain on track for the second half of 2026.In the non-squamous tumors cohort, enrollment is expected to be completed by the end of Q2 2026, and data readout is targeted for the first half of 2027.According to Piper Sandler, investors are now questioning whether the impressive effect size seen in Akeso's HARMONi-6 can be replicated in Summit's global HARMONi-3.HARMONi-6 is a trial conducted in China and sponsored by Akeso, which evaluates ivonescimab in combination with platinum-based chemotherapy compared with the drug tislelizumab and platinum-based chemotherapy in non-small cell lung cancer.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SMMT stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user dismissed the selloff as an overreaction.<stembedurl>https://www.stocktwits.com/northern18738901/message/652058452</stembedurl>Another echoed the sentiment, expressing optimism for the stock to rally back up over $18 in two weeks.<stembedurl>https://www.stocktwits.com/BobBijawklah/message/652053579</stembedurl><a href="https://stocktwits.com/symbol/SMMT">SMMT stock</a> has fallen 35% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nspr-rallies-after-hours-on-fda-green-light-for-key-stroke-prevention-trial/cZQVklHReeA">NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update

Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier.

Equity

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Time to Sell?

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down - What's Next...

Summit Therapeutics Stock Dips After Q1 Financial Report

Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first quarter financial results. Here's what you should know.read more...

Futures Rise, Oil Slides On Iran Ceasefire Optimism After Best Month For Stocks Since 2020

Futures Rise, Oil Slides On Iran Ceasefire Optimism After Best Month For Stocks Since 2020 US equity futures are higher, set for a new all time high, as the rally that's pushed Wall Street to record...

Summit Therapeutics PLC $SMMT Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its holdings in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) by 13.7% during the 4th quarter, according to its most recent disclosure with the SEC...

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.27	--	--	N/A
Q1 '26	-$0.27	-$0.24	10.85%	BEAT
Q4 '25	-$0.09	-$0.29	-233.67%	MISSED
Q3 '25	-$0.18	-$0.31	-76.36%	MISSED
Q2 '25	-$0.09	-$0.76	-736.88%	MISSED

SMMT
Summit Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest SMMT News

SMMTSummit Therapeutics Inc